ST. LOUIS, Sept. 17, 2024 /PRNewswire/ -- In a lawsuit filed in federal court in Missouri, Express Scripts by Evernorth, a subsidiary of The Cigna Group (NYSE: CI), demanded that the Federal Trade Commission ("FTC" or the "Commission") retract its July 2024 report, which is filled with false and misleading claims about the pharmacy benefit management (PBM) industry and fails to serve the interests of American consumers.
Information about Express Scripts' lawsuit to protect those it serves is available at https://www.evernorth.com/advocate.
"The FTC has taken unconstitutional actions in publishing a report that ignores the evidence provided by our company and other PBMs, demonstrates clear ideological bias and advances a false and damaging narrative – a narrative that could harm the health care system by removing essential checks and balances which would result in higher drug prices for American consumers," said Andrea Nelson, Chief Legal Officer for The Cigna Group. "We don't take this step lightly, but as advocates working to lower drug prices for millions of Americans and the employers, labor unions, and government agencies that provide their prescription drug benefits, we cannot let the FTC's unlawful actions and false information stand."
For more than two years, Express Scripts fully cooperated with the FTC study into the PBM industry, meeting the agency's extensive demands for data and information. The FTC's report disregarded the millions of documents and terabytes of data produced by Express Scripts and other PBMs. As a result, the report is riddled with false statements, misleading insinuations and violates the Commission's duty to follow due process and serve the public interest.
The Facts About How Express Scripts Lowers the Cost of Prescription Drugs
"Our 18,000 Express Scripts colleagues work every day to improve health and lower the cost of medications for the millions of Americans we serve," said Eric Palmer, President and CEO of Evernorth Health Services. "Our clinicians and clinical programs perform thousands of critical medication safety checks on each prescription, and we are constantly innovating to improve medication access and affordability. In a world where pharmaceutical manufacturers continue to raise the price of medications every year, Express Scripts' work is more important than ever, and we won't let misinformation or false accusations deter us from our mission."
Express Scripts and other PBMs only exist because they provide real value, driving lower net drug costs for employers, labor unions and other plan sponsors and their members. Express Scripts achieved approximately $38 billion in savings for clients last year alone.
There is no support for claims that PBMs are responsible for high drug costs.
For more information about Express Scripts' work to make medications more affordable and accessible, visit https://www.evernorth.com/express-scripts-facts.
An overview of Express Scripts' complaint, which argues the Commission's report violates the U.S. Constitution and federal law, and the full text are available here.
About Evernorth Health Services
Evernorth Health Services creates pharmacy, care and benefits solutions to improve health and increase vitality. We relentlessly innovate to make the prediction, prevention and treatment of illness and disease more accessible to millions of people. Evernorth capabilities are powered by our businesses, including Express Scripts, Express Scripts® Pharmacy, Accredo, eviCore and MDLIVE, along with holistic Evernorth platforms and solutions that move people and organizations forward. All Evernorth solutions are serviced and provided by or through operating affiliates of Evernorth Health, a wholly owned subsidiary of The Cigna Group (NYSE: CI), or third-party partners. Learn more at evernorth.com.
Media Contact
Justine Sessions
860-810-6523
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$329.66 |
Daily Change: | 6.26 1.94 |
Daily Volume: | 749,625 |
Market Cap: | US$91.690B |
October 31, 2024 September 12, 2024 September 12, 2024 August 01, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB